Basic Search  |  Summaries  |  Advanced SearchPenalty: £130,000,000
Year: 2021
Date: 15 July, 2021
Offence Group: competition-related offences
Offence Type: price-fixing or anti-competitive practices
Violation Description: Accord-UK and, for their ownership periods, its parent companies Intas and Accord and its former parent firm Allergan, were fined £155 million for charging the NHS excessive and unfair prices for hydrocortisone tablets for almost 10 years, from 2008 to 2018. The fine was reinstated after appeals in 2024, but reduced to nearly £130 million.
Agency: Competition and Markets Authority
HQ Country of Parent: India
Ownership Structure of Parent: privately held
Major Industry of Parent: pharmaceuticals
Specific Industry of Parent: pharmaceuticals
Source of Data: (click here)
Source Notes: The CMA also fined Accord-UK and Allergan as former parent a further £66 million for paying two would-be competitors to stay out of the market, which were still under appeal as of September 2024.